85 related articles for article (PubMed ID: 11821877)
1. MMP inhibitors: glimmers of hope amidst clinical failures.
Dove A
Nat Med; 2002 Feb; 8(2):95. PubMed ID: 11821877
[No Abstract] [Full Text] [Related]
2. [Tumor metastasis and MMP inhibitor].
Sato H
Clin Calcium; 2006 Apr; 16(4):621- 26. PubMed ID: 16582513
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach.
Bachmeier BE; Iancu CM; Jochum M; Nerlich AG
Expert Rev Anticancer Ther; 2005 Feb; 5(1):149-63. PubMed ID: 15757447
[TBL] [Abstract][Full Text] [Related]
4. Strategies for MMP inhibition in cancer: innovations for the post-trial era.
Overall CM; López-Otín C
Nat Rev Cancer; 2002 Sep; 2(9):657-72. PubMed ID: 12209155
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin.
Ronco P; Lelongt B; Piedagnel R; Chatziantoniou C
Semin Nephrol; 2007 May; 27(3):352-62. PubMed ID: 17533011
[TBL] [Abstract][Full Text] [Related]
6. Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.
Acharya MR; Venitz J; Figg WD; Sparreboom A
Drug Resist Updat; 2004 Jun; 7(3):195-208. PubMed ID: 15296861
[TBL] [Abstract][Full Text] [Related]
7. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.
Peterson JT
Cardiovasc Res; 2006 Feb; 69(3):677-87. PubMed ID: 16413004
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight inhibitors of matrix metalloproteinases can enhance the expression of matrix metalloproteinase-2 (gelatinase A) without inhibiting its activation.
Kerkvliet EH; Jansen ID; Schoenmaker TA; Docherty AJ; Beertsen W; Everts V
Cancer; 2003 Mar; 97(6):1582-8. PubMed ID: 12627524
[TBL] [Abstract][Full Text] [Related]
9. Lymphangioleiomyomatosis.
Fernández-Fernández FJ; Buño-Ramilo B; Sesma P
Eur J Intern Med; 2009 Jan; 20(1):e24. PubMed ID: 19237077
[No Abstract] [Full Text] [Related]
10. Matrix metalloproteinases and colon anastomosis repair: a new indication for pharmacological inhibition?
Agren MS; Jorgensen LN; Delaissé JM
Mini Rev Med Chem; 2004 Sep; 4(7):769-78. PubMed ID: 15379644
[TBL] [Abstract][Full Text] [Related]
11. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Lara PN; Stadler WM; Longmate J; Quinn DI; Wexler J; Van Loan M; Twardowski P; Gumerlock PH; Vogelzang NJ; Vokes EE; Lenz HJ; Doroshow JH; Gandara DR
Clin Cancer Res; 2006 Mar; 12(5):1556-63. PubMed ID: 16533781
[TBL] [Abstract][Full Text] [Related]
13. Human mesenchymal stem cell derived osteoblasts degrade organic bone matrix in vitro by matrix metalloproteinases.
Parikka V; Väänänen A; Risteli J; Salo T; Sorsa T; Väänänen HK; Lehenkari P
Matrix Biol; 2005 Sep; 24(6):438-47. PubMed ID: 16098718
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases: useful and deleterious.
Ganea E; Trifan M; Laslo AC; Putina G; Cristescu C
Biochem Soc Trans; 2007 Aug; 35(Pt 4):689-91. PubMed ID: 17635123
[TBL] [Abstract][Full Text] [Related]
15. CMT-3. CollaGenex.
Fingleton B
Curr Opin Investig Drugs; 2003 Dec; 4(12):1460-7. PubMed ID: 14763133
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and their inhibitors in malignant and autoreactive pericardial effusion.
Lamparter S; Schoppet M; Christ M; Pankuweit S; Maisch B
Am J Cardiol; 2005 May; 95(9):1065-9. PubMed ID: 15842972
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinases and cancer.
Cox G; O'Byrne KJ
Anticancer Res; 2001; 21(6B):4207-19. PubMed ID: 11908674
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
19. [Treatment with bisphosphonates].
Drevs J
Med Monatsschr Pharm; 2004 Jun; 27(6):208. PubMed ID: 15230520
[No Abstract] [Full Text] [Related]
20. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases.
Kieseier BC; Archelos JJ; Hartung HP
Arch Neurol; 2004 Jun; 61(6):929-32. PubMed ID: 15210533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
